Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy [0.03%]
脂蛋白(a)、胆固醇、甘油三酯水平与易损冠状动脉斑块：PROSPECT II 子研究
David Erlinge,Sotirios Tsimikas,Michael Maeng et al.
David Erlinge et al.
Background: Although lipoprotein(a) (Lp[a]) has been associated with acute myocardial infarction (MI), the relationship between Lp(a) and the presence of high-risk "vulnerable" coronary plaques has not been studied. ...
Harlan M Krumholz
Harlan M Krumholz
Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patient [0.03%]
在高风险患者中使用简化的与延长的双联抗血小板治疗方案后的总缺血及出血事件的复发事件分析：来自MASTER DAPT试验的结果
Dario Bongiovanni,Antonio Landi,Enrico Frigoli et al.
Dario Bongiovanni et al.
Background: The effect of dual antiplatelet therapy (DAPT) duration on total events in patients at high bleeding risk (HBR) after PCI is unclear. Objectiv...
Impact of optical coherence tomography-based post-PCI physiology assessment to predict clinical outcomes: an ILUMIEN-IV substudy [0.03%]
基于光学相干断层扫描的生理功能评估预测经皮冠状动脉介入术后临床预后的价值：ILUMIEN IV子研究
Thomas W Johnson,Brian A Bergmark,Kevin Croce et al.
Thomas W Johnson et al.
Background: A novel optical coherence tomography (OCT)-based physiology assessment technique, virtual flow reserve (VFR), has been demonstrated to perform as a reliable surrogate for invasive physiology. ...
Biolimus-Eluting Biomatrix Stent Versus a Dual-Therapy Sirolimus-Eluting Stent in PCI: SORT OUT XI Randomized Trial [0.03%]
药物洗脱生物基质支架与双治疗西罗莫司洗脱支架在PCI中的对比研究：SORT OUT XI 随机试验
Ashkan Eftekhari,Lisette Okkels Jensen,Karsten Veien et al.
Ashkan Eftekhari et al.
Background: Percutaneous coronary intervention (PCI) with new generation drug eluting stents (DES) is still associated with risk of target lesion failure (TLF). The biolimus A9 eluting BioMatrix Alpha® stent (BES) with b...
Impact of Vutrisiran on Functional Capacity and Quality of Life in ATTR Cardiomyopathy: HELIOS-B Analysis [0.03%]
Vutrisiran对ATTR心肌病患者运动能力和生活质量的影响：HELIOS-B研究分析
Omar K Siddiqi,Frederick L Ruberg,Deepa M Gopal
Omar K Siddiqi
Joban Vaishnav,Brett W Sperry
Joban Vaishnav
Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy [0.03%]
血清转运蛋白作为ATTR心肌病治疗反应生物标志物的作用
Jessica A Regan,Michelle M Kittleson,Michel G Khouri et al.
Jessica A Regan et al.
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy [0.03%]
早期乙酸阿格列汀致血清甲状腺转运蛋白水平升高可独立预测TTR心肌病患者预后改善
Mathew S Maurer,Daniel P Judge,Julian D Gillmore et al.
Mathew S Maurer et al.
Background: Acoramidis is a novel, high-affinity stabilizer that achieves ≥90% transthyretin (TTR) stabilization. The phase 3 study, ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardio...
Kushal T Kadakia,Michelle M Kittleson,Harlan M Krumholz
Kushal T Kadakia